Detalles de la búsqueda
1.
Immune Checkpoint Inhibitors in "Special" NSCLC Populations: A Viable Approach?
Int J Mol Sci
; 24(16)2023 Aug 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37628803
2.
A phase II, open-label, single-arm trial of carboplatin plus etoposide with bevacizumab and atezolizumab in patients with extended-stage small-cell lung cancer (CeLEBrATE study): background, design and rationale.
Future Oncol
; 18(7): 771-779, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-35068173
3.
Monitoring Somatic Genetic Alterations in Circulating Cell-Free DNA/RNA of Patients with "Oncogene-Addicted" Advanced Lung Adenocarcinoma: A Real-World Clinical Study.
Int J Mol Sci
; 23(15)2022 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35955679
4.
Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol
; 22(10): 1458-1467, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34543613
5.
A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC.
Cancer Immunol Immunother
; 70(6): 1667-1678, 2021 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-33315149
6.
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.
Lancet Oncol
; 21(11): 1455-1464, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-33152285
7.
Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL).
Br J Cancer
; 123(1): 26-32, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32346071
8.
Fighting cancer in coronavirus disease era: organization of work in medical oncology departments in Emilia Romagna region of Italy.
Future Oncol
; 16(20): 1433-1439, 2020 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-32437242
9.
Endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: extending endocrine sensitivity.
Future Oncol
; 16(5): 129-145, 2020 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-31849236
10.
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial.
BMC Med
; 17(1): 207, 2019 11 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-31747948
11.
Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study.
Lancet Oncol
; 19(2): 249-256, 2018 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-29326029
12.
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.
Lancet Oncol
; 19(4): 474-485, 2018 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-29482983
13.
Everolimus Plus Exemestane in Advanced Breast Cancer: Safety Results of the BALLET Study on Patients Previously Treated Without and with Chemotherapy in the Metastatic Setting.
Oncologist
; 22(6): 648-654, 2017 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-28432226
14.
Correction to: Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL).
Br J Cancer
; 125(2): 306, 2021 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-34012035
15.
Current views on anthracycline cardiotoxicity.
Heart Fail Rev
; 21(5): 621-34, 2016 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-27230651
16.
Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer.
Oncologist
; 20(9): 1001-10, 2015 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-26245675
17.
Adjuvant hormonal therapy and fertility preservation in premenopausal breast cancer: a survey among Italian oncologists.
Future Oncol
; 11(8): 1181-9, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-25832875
18.
Metastatic site patterns by intrinsic subtype and HER2DX in early HER2-positive breast cancer.
J Natl Cancer Inst
; 116(1): 69-80, 2024 01 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37676829
19.
Single-Agent Trabectedin Versus Physician's Choice Chemotherapy in Patients With Recurrent Ovarian Cancer With BRCA-Mutated and/or BRCAness Phenotype: A Randomized Phase III Trial.
J Clin Oncol
; 42(13): 1488-1498, 2024 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38315944
20.
Type of adjuvant endocrine therapy and disease-free survival in patients with early HR-positive/HER2-positive BC: analysis from the phase III randomized ShortHER trial.
NPJ Breast Cancer
; 9(1): 6, 2023 Feb 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36739285